Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 5/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 6/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14865741 | 0.91 | TGFBR1 (0.42) | PRKD1TGFBR1CCNT1ATRRAF1 | |
| SCHEMBL14865786 | 0.90 | RAF1 (0.38) | PRKD1TGFBR1CCNT1ATRATM | |
| SCHEMBL14866870 | 0.88 | ATR (0.50) | ATRATM | |
| SCHEMBL14865610 | 0.86 | ATR (0.41) | ATRRAF1BRAFPIM1PIM3 | |
| SCHEMBL14865695 | 0.86 | PRKD1 (0.52) | PRKD1TGFBR1CCNT1ATRATM | |
| SCHEMBL14865751 | 0.85 | RAF1 (0.36) | ATRRAF1BRAFMAP4K4PIM1 | |
| SCHEMBL14865746 | 0.84 | TGFBR1 (0.41) | PRKD1TGFBR1CCNT1ATRATM | |
| SCHEMBL14865896 | 0.82 | RAF1 (0.34) | ATRRAF1BRAFPIM1PIM3 | |
| SCHEMBL14865823 | 0.81 | PRKD1 (0.48) | PRKD1TGFBR1ATRATMRAF1 | |
| SCHEMBL14865735 | 0.81 | PRKD1 (0.48) | PRKD1TGFBR1ATRATMRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130095193-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095193-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | PRKD1 89/4885TGFBR1 2151/4885CCNT1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.